{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:12:56Z","timestamp":1793056376865,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"DOI":"10.1007\/s42000-026-00806-y","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:45:53Z","timestamp":1784303153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of osilodrostat in patients with ectopic Cushing\u2019s syndrome"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Arroyo-Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Contreras-Saldarriaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-4343","authenticated-orcid":false,"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"806_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/S11102-018-0894-2","volume":"21","author":"M Araujo Castro","year":"2018","unstructured":"Araujo Castro M, Marazuela Azpiroz M (2018) Two types of ectopic Cushing syndrome or a continuum? Rev Pituit 21:535\u2013544. https:\/\/doi.org\/10.1007\/S11102-018-0894-2","journal-title":"Rev Pituit"},{"key":"806_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/JAMA.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M, Cushing Syndrome A, Review (2023) JAMA 330:170\u2013181. https:\/\/doi.org\/10.1001\/JAMA.2023.11305","journal-title":"JAMA"},{"key":"806_CR3","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/J.BEEM.2021.101521","volume":"35","author":"OA Hakami","year":"2021","unstructured":"Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35:101521. https:\/\/doi.org\/10.1016\/J.BEEM.2021.101521","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"806_CR4","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","volume":"402","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Gatto F, Wildemberg LE, Fleseriu M (2023) Cushing\u2019s syndrome. Lancet (London England) 402:2237\u20132252. https:\/\/doi.org\/10.1016\/S0140-6736(23)01961-X","journal-title":"Lancet (London England)"},{"key":"806_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","volume":"367","author":"J Newell-Price","year":"2006","unstructured":"Newell-Price J, Bertagna X, Grossman ABA, Nieman LKLLK (2006) Cushing\u2019s syndrome. Lancet 367:1605\u20131617. https:\/\/doi.org\/10.1016\/S0140-6736(06)68699-6","journal-title":"Lancet"},{"key":"806_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/jc.2005-1542","volume":"91","author":"AM Isidori","year":"2006","unstructured":"Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH et al (2006) The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91:371\u2013377. https:\/\/doi.org\/10.1210\/jc.2005-1542","journal-title":"J Clin Endocrinol Metab"},{"key":"806_CR7","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/EJE-19-0877","volume":"182","author":"J Young","year":"2020","unstructured":"Young J, Haissaguerre M, Viera-Pinto O, Chabre O, Baudin E, Tabarin A (2020) MANAGEMENT OF ENDOCRINE DISEASE: Cushing\u2019s syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol 182:R29\u201358. https:\/\/doi.org\/10.1530\/EJE-19-0877","journal-title":"Eur J Endocrinol"},{"key":"806_CR8","doi-asserted-by":"publisher","first-page":"823247096209180","DOI":"10.1177\/2324709620918080","volume":"8","author":"L Wade","year":"2020","unstructured":"Wade L, Kitching P, De Winton E (2020) Ectopic ACTH Secretion Secondary to Metastatic Acinic Cell Carcinoma of the Parotid Gland: A Case Report and Review of Current Evidence for Systemic Therapy. J Investig Med High Impact Case Rep 8:82324709620918080. https:\/\/doi.org\/10.1177\/2324709620918080","journal-title":"J Investig Med High Impact Case Rep"},{"key":"806_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/EJE-19-0464","volume":"181","author":"E Valassi","year":"2019","unstructured":"Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R et al (2019) High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry. Eur J Endocrinol 181:461\u2013472. https:\/\/doi.org\/10.1530\/EJE-19-0464","journal-title":"Eur J Endocrinol"},{"key":"806_CR10","doi-asserted-by":"publisher","first-page":"204201882110585","DOI":"10.1177\/20420188211058583","volume":"13","author":"A Pence","year":"2022","unstructured":"Pence A, McGrath M, Lee SL, Raines DE (2022) Pharmacological management of severe Cushing\u2019s syndrome: the role of etomidate. Ther Adv Endocrinol Metab 13:20420188211058583. https:\/\/doi.org\/10.1177\/20420188211058583","journal-title":"Ther Adv Endocrinol Metab"},{"key":"806_CR11","doi-asserted-by":"publisher","first-page":"e13030","DOI":"10.1111\/JNE.13030","volume":"33","author":"I Lase","year":"2021","unstructured":"Lase I, Gr\u00f6nberg M, Norl\u00e9n O, St\u00e5lberg P, Welin S, Janson ET (2021) Adrenalectomy in ectopic Cushing\u2019s syndrome: A retrospective cohort study from a tertiary care centre. J Neuroendocrinol 33:e13030. https:\/\/doi.org\/10.1111\/JNE.13030","journal-title":"J Neuroendocrinol"},{"key":"806_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/J.SURG.2022.03.014","volume":"172","author":"JP Landry","year":"2022","unstructured":"Landry JP, Clemente-Gutierrez U, Pieterman CRC, Chiang YJ, Waguespack SG, Jimenez C et al (2022) Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery 172:559\u2013566. https:\/\/doi.org\/10.1016\/J.SURG.2022.03.014","journal-title":"Surgery"},{"key":"806_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","volume":"7","author":"RA Feelders","year":"2019","unstructured":"Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A (2019) Advances in the medical treatment of Cushing. \u2019s syndrome 7:300\u2013312. https:\/\/doi.org\/10.1016\/S2213-8587(18)30155-4","journal-title":"\u2019s syndrome"},{"key":"806_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/14656566.2023.2192349","volume":"24","author":"M Martino","year":"2023","unstructured":"Martino M, Aboud N, Lucchetti B, Salvio G, Arnaldi G (2023) An evaluation of pharmacological options for Cushing\u2019s disease: what are the state-of-the-art options? Expert Opin Pharmacother 24:557\u2013576. https:\/\/doi.org\/10.1080\/14656566.2023.2192349","journal-title":"Expert Opin Pharmacother"},{"key":"806_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8:748\u2013761. https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"806_CR16","doi-asserted-by":"publisher","first-page":"E2882","DOI":"10.1210\/CLINEM\/DGAC178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A et al (2022) Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab 107:E2882\u2013E2895. https:\/\/doi.org\/10.1210\/CLINEM\/DGAC178","journal-title":"J Clin Endocrinol Metab"},{"key":"806_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C et al (2022) Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol 187:531\u2013541. https:\/\/doi.org\/10.1530\/EJE-22-0317","journal-title":"Eur J Endocrinol"},{"key":"806_CR18","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1210\/CLINEM\/DGAC691","volume":"108","author":"A Dormoy","year":"2023","unstructured":"Dormoy A, Haissaguerre M, Vitellius G, Cao C, Do, Geslot A, Drui D et al (2023) Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. J Clin Endocrinol Metab 108:1475\u20131487. https:\/\/doi.org\/10.1210\/CLINEM\/DGAC691","journal-title":"J Clin Endocrinol Metab"},{"key":"806_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"key":"806_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","volume":"13","author":"MDJ Peters","year":"2015","unstructured":"Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB (2015) Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc 13:141\u2013146. https:\/\/doi.org\/10.1097\/XEB.0000000000000050","journal-title":"Int J Evid Based Healthc"},{"key":"806_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"issue":"7","key":"806_CR22","first-page":"e1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions. explanation elaboration 6(7):e1000100","journal-title":"explanation elaboration"},{"key":"806_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000543177","volume":"18","author":"T Koizumi","year":"2025","unstructured":"Koizumi T, Sato A, Kitajima K, Yamazaki M, Kanazawa S, Notake T et al (2025) An ACTH-Producing Neuroendocrine Tumor: Clinical Course of Multidisciplinary Therapy Including Peptide Receptor Radionuclide Therapy - A Case Report. Case Rep Oncol 18:181\u2013189. https:\/\/doi.org\/10.1159\/000543177","journal-title":"Case Rep Oncol"},{"key":"806_CR24","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/S12020-024-04135-1","volume":"87","author":"L Dzialach","year":"2025","unstructured":"Dzialach L, Sobolewska J, Respondek W, Wojciechowska-Luzniak A, Kuca P, Witek P (2025) Is there still a place for etomidate in the management of Cushing\u2019s syndrome? The experience of a single center of low-dose etomidate and combined etomidate-osilodrostat treatment in severe hypercortisolemia. Endocrine 87:1305\u20131313. https:\/\/doi.org\/10.1007\/S12020-024-04135-1","journal-title":"Endocrine"},{"issue":"2","key":"806_CR25","doi-asserted-by":"publisher","first-page":"luae008","DOI":"10.1210\/JCEMCR\/LUAE008","volume":"27","author":"F Sawabe","year":"2024","unstructured":"Sawabe F, Hayafusa R, Kosugi R, Ariyasu H (2024) A Case of an Ectopic ACTH-Producing Tumor With Adrenal Shrinkage During Osilodrostat Administration. JCEM Case Rep 27(2):luae008. https:\/\/doi.org\/10.1210\/JCEMCR\/LUAE008","journal-title":"JCEM Case Rep"},{"key":"806_CR26","doi-asserted-by":"publisher","first-page":"bvaf027","DOI":"10.1210\/JENDSO\/BVAF027","volume":"9","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Auchus RJ, Bancos I, Biller BMKK (2025) Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations. J Endocr Soc 9:bvaf027. https:\/\/doi.org\/10.1210\/JENDSO\/BVAF027","journal-title":"J Endocr Soc"},{"key":"806_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/J.ANDO.2021.11.007","volume":"83","author":"AC Paepegaey","year":"2022","unstructured":"Paepegaey AC, Dot JM, Beauvy J, Juttet P, Le Berre JP (2022) Pembrolizumab-induced cyclic ACTH-dependent Cushing\u2019s syndrome treated by a block-and-replace approach with osilodrostat. Ann Endocrinol (Paris) 83:73\u201375. https:\/\/doi.org\/10.1016\/J.ANDO.2021.11.007","journal-title":"Ann Endocrinol (Paris)"},{"key":"806_CR28","doi-asserted-by":"publisher","first-page":"1492187","DOI":"10.3389\/FONC.2025.1492187","volume":"15","author":"A Zdrojowy-We\u0142na","year":"2025","unstructured":"Zdrojowy-We\u0142na A, Bolanowski M, Syrycka J, Jawiarczyk-Przyby\u0142owska A, Kuliczkowska-P\u0142aksej J (2025) Case Report: Thymic neuroendocrine tumor with metastasis to the breast causing ectopic Cushing\u2019s syndrome. Front Oncol 15:1492187. https:\/\/doi.org\/10.3389\/FONC.2025.1492187","journal-title":"Front Oncol"},{"key":"806_CR29","doi-asserted-by":"publisher","first-page":"e77459","DOI":"10.7759\/CUREUS.77459","volume":"17","author":"H Nakabayashi","year":"2025","unstructured":"Nakabayashi H, Akiyama M, Yodokawa T, Itoh W, Taguchi A, Takeda K et al (2025) A Pheochromocytoma With Adrenocorticotropic Hormone Secretion and Subsequent Fatal Outcome: A Case Report. Cureus 17:e77459. https:\/\/doi.org\/10.7759\/CUREUS.77459","journal-title":"Cureus"},{"issue":"2","key":"806_CR30","doi-asserted-by":"publisher","first-page":"luae255","DOI":"10.1210\/JCEMCR\/LUAE255","volume":"3","author":"K Lee","year":"2025","unstructured":"Lee K, Mendes Pessoa C, Huang W (2025) Successful Treatment of Severe Ectopic ACTH-Dependent Cushing Syndrome Complicated by Hypocalcemia With Osilodrostat. JCEM Case Rep 3(2):luae255. https:\/\/doi.org\/10.1210\/JCEMCR\/LUAE255","journal-title":"JCEM Case Rep"},{"issue":"4","key":"806_CR31","doi-asserted-by":"publisher","first-page":"luad101","DOI":"10.1210\/JCEMCR\/LUAD101","volume":"1","author":"K Blew","year":"2023","unstructured":"Blew K, Van Mater D, Page L (2023) Successful Management of Cushing Syndrome From Ectopic ACTH Secretion in an Adolescent With Osilodrostat. JCEM Case Rep 1(4):luad101. https:\/\/doi.org\/10.1210\/JCEMCR\/LUAD101","journal-title":"JCEM Case Rep"},{"key":"806_CR32","doi-asserted-by":"publisher","unstructured":"H\u00e1na V, Brutvan T, Krausov\u00e1 A, Kr\u0161ek M, H\u00e1na V (2023) Severe Cushing\u2019s syndrome from an ectopic adrenocorticotropic hormone-secreting neuroendocrine tumour treated by osilodrostat. Endocrinol Diabetes Metab Case Rep 2023. https:\/\/doi.org\/10.1530\/EDM-23-0076","DOI":"10.1530\/EDM-23-0076"},{"key":"806_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/S11102-022-01268-2","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK (2022) Treatment of Cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary 25:795\u2013809. https:\/\/doi.org\/10.1007\/S11102-022-01268-2","journal-title":"Pituitary"},{"key":"806_CR34","doi-asserted-by":"publisher","first-page":"L13","DOI":"10.1530\/EJE-21-0147","volume":"184","author":"L Bessi\u00e8ne","year":"2021","unstructured":"Bessi\u00e8ne L, Bonnet F, Tenenbaum F, Jozwiak M, Corchia A, Bertherat J et al (2021) Rapid control of severe ectopic Cushing\u2019s syndrome by oral osilodrostat monotherapy. Eur J Endocrinol 184:L13\u2013L15. https:\/\/doi.org\/10.1530\/EJE-21-0147","journal-title":"Eur J Endocrinol"},{"key":"806_CR35","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/EJE-20-0557","volume":"183","author":"M Haissaguerre","year":"2020","unstructured":"Haissaguerre M, Puerto M, Nunes ML, Tabarin A (2020) Efficacy and tolerance of osilodrostat in patients with severe Cushing\u2019s syndrome due to non-pituitary cancers. Eur J Endocrinol 183:L7\u2013L6. https:\/\/doi.org\/10.1530\/EJE-20-0557","journal-title":"Eur J Endocrinol"},{"key":"806_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000527824","volume":"16","author":"CT Heleno","year":"2023","unstructured":"Heleno CT, Hong SPD, Cho HG, Kim MJ, Park Y, Chae YK (2023) Cushing\u2019s Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat. Case Rep Oncol 16:130\u2013134. https:\/\/doi.org\/10.1159\/000527824","journal-title":"Case Rep Oncol"},{"key":"806_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/17446651.2016.1123615","volume":"11","author":"KI Alexandraki","year":"2016","unstructured":"Alexandraki KI, Grossman AB (2016) Current strategies for the treatment of severe Cushing\u2019s syndrome. Expert Rev Endocrinol Metab 11:65\u201379. https:\/\/doi.org\/10.1586\/17446651.2016.1123615","journal-title":"Expert Rev Endocrinol Metab"},{"key":"806_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/EJE-12-0274","volume":"167","author":"VA Preda","year":"2012","unstructured":"Preda VA, Sen J, Karavitaki N, Grossman AB (2012) Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: A review. Eur J Endocrinol 167:137\u2013143. https:\/\/doi.org\/10.1530\/EJE-12-0274","journal-title":"Eur J Endocrinol"},{"key":"806_CR39","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/JC.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A et al (2014) LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99:1375\u20131383. https:\/\/doi.org\/10.1210\/JC.2013-2117","journal-title":"J Clin Endocrinol Metab"},{"key":"806_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/S11102-015-0692-Z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C et al (2016) Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease. Pituitary 19:138\u2013148. https:\/\/doi.org\/10.1007\/S11102-015-0692-Z","journal-title":"Pituitary"},{"issue":"2","key":"806_CR41","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-21-1008","volume":"186","author":"A Tabarin","year":"2022","unstructured":"Tabarin A, Haissaguerre M, Lassole H, Jannin A, Paepegaey AC, Chabre O et al (2022) Efficacy and tolerance of osilodrostat in patients with Cushing\u2019s syndrome due to adrenocortical carcinomas. Eur J Endocrinol 186(2):K1\u2013K4. https:\/\/doi.org\/10.1530\/EJE-21-1008","journal-title":"Eur J Endocrinol"},{"key":"806_CR42","doi-asserted-by":"publisher","first-page":"K11","DOI":"10.1093\/EJENDO\/LVAF185","volume":"193","author":"C Piazzola","year":"2025","unstructured":"Piazzola C, Castinetti F, Von Fabeck K, Simon N (2025) A preliminary model to tailor osilodrostat in patients with Adrenocorticotropic hormone (ACTH)-dependent Cushing\u2019s syndrome. Eur J Endocrinol 193:K11\u2013K15. https:\/\/doi.org\/10.1093\/EJENDO\/LVAF185","journal-title":"Eur J Endocrinol"},{"key":"806_CR43","doi-asserted-by":"publisher","first-page":"501654","DOI":"10.1016\/J.ENDINU.2025.501654","volume":"72","author":"M Araujo-Castro","year":"2025","unstructured":"Araujo-Castro M, Garc\u00eda-Centeno R, Aller J, Marazuela M, Soto A, G\u00e1lvez M\u00c1 et al (2025) Executive summary of the consensus document for the management of severe Cushing\u2019s syndrome: Consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN). Endocrinol Diabetes y Nutr 72:501654. https:\/\/doi.org\/10.1016\/J.ENDINU.2025.501654","journal-title":"Endocrinol Diabetes y Nutr"},{"key":"806_CR44","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1530\/EJE-18-0062","volume":"178","author":"X Bertagna","year":"2018","unstructured":"Bertagna X (2018) MANAGEMENT OF ENDOCRINE DISEASE: Can we cure Cushing\u2019s disease? A personal view. Eur J Endocrinol 178:R183\u2013200. https:\/\/doi.org\/10.1530\/EJE-18-0062","journal-title":"Eur J Endocrinol"},{"key":"806_CR45","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-20-0352","volume":"183","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Nieman LK, Reincke M, Tabarin A (2020) ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing\u2019s syndrome. Eur J Endocrinol 183:G1\u20137. https:\/\/doi.org\/10.1530\/EJE-20-0352","journal-title":"Eur J Endocrinol"},{"key":"806_CR46","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/CLINEM\/DGAB122","volume":"106","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Nieman LK, Reincke M, Newell-Price J (2021) Approach to the Patient Treated with Steroidogenesis Inhibitors. J Clin Endocrinol Metab 106:2114\u20132123. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB122","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"806_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1210\/ENDREV\/BNAF042","volume":"47","author":"M Araujo-Castro","year":"2026","unstructured":"Araujo-Castro M, Lamas C, Nowak E, Newell-Price J, Reincke M, Castinetti F (2026) Update and practical recommendations for the use of medical treatment of Cushing\u00b4s syndrome. Endocr Rev 47(3):301\u2013328. https:\/\/doi.org\/10.1210\/ENDREV\/BNAF042","journal-title":"Endocr Rev"},{"key":"806_CR48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/S11102-018-0894-2","volume":"21","author":"M Araujo Castro","year":"2018","unstructured":"Araujo Castro M, Marazuela A (2018) Two types of ectopic Cushing syndrome or a continuum? Rev Pituit 21:535\u2013544. https:\/\/doi.org\/10.1007\/S11102-018-0894-2","journal-title":"Rev Pituit"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00806-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00806-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00806-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:45:54Z","timestamp":1784303154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-026-00806-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":48,"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00806-y","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.C. received speakers\u2019 honoraria, research funding, and consulting fees from Esteve and Recordati and was involved in research studies with Lundbeck; B.B. have received speaking fees, advisory roles, travel support, and research grants from Recordati. The other authors have not received any honoraria, consultancy fees, or financial support from any pharmaceutical companies.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}